These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 15899815)

  • 1. Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation.
    Knauf JA; Ma X; Smith EP; Zhang L; Mitsutake N; Liao XH; Refetoff S; Nikiforov YE; Fagin JA
    Cancer Res; 2005 May; 65(10):4238-45. PubMed ID: 15899815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer.
    Romei C; Ciampi R; Faviana P; Agate L; Molinaro E; Bottici V; Basolo F; Miccoli P; Pacini F; Pinchera A; Elisei R
    Endocr Relat Cancer; 2008 Jun; 15(2):511-20. PubMed ID: 18509003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thyrotropin signaling confers more aggressive features with higher genomic instability on BRAF(V600E)-induced thyroid tumors in a mouse model.
    Orim F; Bychkov A; Shimamura M; Nakashima M; Ito M; Matsuse M; Kurashige T; Suzuki K; Saenko V; Nagayama Y; Yamashita S; Mitsutake N
    Thyroid; 2014 Mar; 24(3):502-10. PubMed ID: 23924149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma.
    Costa AM; Herrero A; Fresno MF; Heymann J; Alvarez JA; Cameselle-Teijeiro J; García-Rostán G
    Clin Endocrinol (Oxf); 2008 Apr; 68(4):618-34. PubMed ID: 18070147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Postnatal expression of BRAFV600E does not induce thyroid cancer in mouse models of thyroid papillary carcinoma.
    Shimamura M; Nakahara M; Orim F; Kurashige T; Mitsutake N; Nakashima M; Kondo S; Yamada M; Taguchi R; Kimura S; Nagayama Y
    Endocrinology; 2013 Nov; 154(11):4423-30. PubMed ID: 23970782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism.
    Durante C; Puxeddu E; Ferretti E; Morisi R; Moretti S; Bruno R; Barbi F; Avenia N; Scipioni A; Verrienti A; Tosi E; Cavaliere A; Gulino A; Filetti S; Russo D
    J Clin Endocrinol Metab; 2007 Jul; 92(7):2840-3. PubMed ID: 17488796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Childhood thyroid carcinoma with BRAFT1799A mutation shows unique pathological features of poor differentiation.
    Kumagai A; Namba H; Mitsutake N; Saenko VA; Ohtsuru A; Ito M; Noh JY; Sugino K; Ito K; Yamashita S
    Oncol Rep; 2006 Jul; 16(1):123-6. PubMed ID: 16786134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aberrant BRAF splicing as an alternative mechanism for oncogenic B-Raf activation in thyroid carcinoma.
    Baitei EY; Zou M; Al-Mohanna F; Collison K; Alzahrani AS; Farid NR; Meyer B; Shi Y
    J Pathol; 2009 Apr; 217(5):707-15. PubMed ID: 19156774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of iodine metabolism genes in human thyroid tissues: evidence for age and BRAFV600E mutation dependency.
    Espadinha C; Santos JR; Sobrinho LG; Bugalho MJ
    Clin Endocrinol (Oxf); 2009 Apr; 70(4):629-35. PubMed ID: 18710471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. No correlation between BRAFV600E mutation and clinicopathological features of papillary thyroid carcinomas in Taiwan.
    Liu RT; Chen YJ; Chou FF; Li CL; Wu WL; Tsai PC; Huang CC; Cheng JT
    Clin Endocrinol (Oxf); 2005 Oct; 63(4):461-6. PubMed ID: 16181240
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conditional BRAFV600E expression induces DNA synthesis, apoptosis, dedifferentiation, and chromosomal instability in thyroid PCCL3 cells.
    Mitsutake N; Knauf JA; Mitsutake S; Mesa C; Zhang L; Fagin JA
    Cancer Res; 2005 Mar; 65(6):2465-73. PubMed ID: 15781663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas.
    Puxeddu E; Moretti S; Elisei R; Romei C; Pascucci R; Martinelli M; Marino C; Avenia N; Rossi ED; Fadda G; Cavaliere A; Ribacchi R; Falorni A; Pontecorvi A; Pacini F; Pinchera A; Santeusanio F
    J Clin Endocrinol Metab; 2004 May; 89(5):2414-20. PubMed ID: 15126572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature.
    Fugazzola L; Puxeddu E; Avenia N; Romei C; Cirello V; Cavaliere A; Faviana P; Mannavola D; Moretti S; Rossi S; Sculli M; Bottici V; Beck-Peccoz P; Pacini F; Pinchera A; Santeusanio F; Elisei R
    Endocr Relat Cancer; 2006 Jun; 13(2):455-64. PubMed ID: 16728573
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HER inhibitor promotes BRAF/MEK inhibitor-induced redifferentiation in papillary thyroid cancer harboring BRAFV600E.
    Cheng L; Jin Y; Liu M; Ruan M; Chen L
    Oncotarget; 2017 Mar; 8(12):19843-19854. PubMed ID: 28423638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer.
    Riesco-Eizaguirre G; Rodríguez I; De la Vieja A; Costamagna E; Carrasco N; Nistal M; Santisteban P
    Cancer Res; 2009 Nov; 69(21):8317-25. PubMed ID: 19861538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduced expression of THRβ in papillary thyroid carcinomas: relationship with BRAF mutation, aggressiveness and miR expression.
    Rosignolo F; Maggisano V; Sponziello M; Celano M; Di Gioia CR; D'Agostino M; Giacomelli L; Verrienti A; Dima M; Pecce V; Durante C
    J Endocrinol Invest; 2015 Dec; 38(12):1283-9. PubMed ID: 26003825
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRAFV600E-Associated Gene Expression Profile: Early Changes in the Transcriptome, Based on a Transgenic Mouse Model of Papillary Thyroid Carcinoma.
    Rusinek D; Swierniak M; Chmielik E; Kowal M; Kowalska M; Cyplinska R; Czarniecka A; Piglowski W; Korfanty J; Chekan M; Krajewska J; Szpak-Ulczok S; Jarzab M; Widlak W; Jarzab B
    PLoS One; 2015; 10(12):e0143688. PubMed ID: 26625260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRAFV600E mutation and X-linked inhibitor of apoptosis expression in papillary thyroid carcinoma.
    Gu LQ; Li FY; Zhao L; Liu Y; Zang XX; Wang TX; Chen HP; Ning G; Zhao YJ
    Thyroid; 2009 Apr; 19(4):347-54. PubMed ID: 19355825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BRAFV600E mutation in the pathogenesis of a large series of papillary thyroid carcinoma in Czech Republic.
    Sykorova V; Dvorakova S; Ryska A; Vcelak J; Vaclavikova E; Laco J; Kodetova D; Kodet R; Cibula A; Duskova J; Hlobilkova A; Astl J; Vesely D; Betka J; Hoch J; Smutny S; Cap J; Vlcek P; Novak Z; Bendlova B
    J Endocrinol Invest; 2010 May; 33(5):318-24. PubMed ID: 20009493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DUSP5 and DUSP6, two ERK specific phosphatases, are markers of a higher MAPK signaling activation in BRAF mutated thyroid cancers.
    Buffet C; Hecale-Perlemoine K; Bricaire L; Dumont F; Baudry C; Tissier F; Bertherat J; Cochand-Priollet B; Raffin-Sanson ML; Cormier F; Groussin L
    PLoS One; 2017; 12(9):e0184861. PubMed ID: 28910386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.